China Biopharma Financing and Licensing Activity Rebounds in September 2026

October 22, 2026 | Industry News

China’s biopharmaceutical sector saw a notable rebound in financing and licensing activity in September 2026, according to industry data published by PharmaDJ on October 13. The report recorded 24 primary-market financing deals totaling approximately US$8.05 billion, alongside 15 out-licensing transactions with reported upfront payments of US$1.05 billion and aggregate potential deal value of US$14.65 billion.

The figures point to continued investor interest in selected biotechnology platforms and sustained international demand for innovative drug assets developed by Chinese companies. However, financing totals and headline licensing values should be interpreted carefully, as individual large transactions can materially influence aggregate figures.

Financing Activity Rebounds, with AI Drug Discovery Attracting Capital

According to PharmaDJ’s September 2026 China Biopharma Tracker, the 24 financing deals totaled US$8.05 billion, up from US$3.97 billion in August.

The reported activity covered several therapeutic and technology areas, including AI-enabled drug discovery, radioligand therapy, targeted protein degradation, cytokine therapies and T-cell engagers. Financing rounds ranged from seed-stage investments to later early-stage rounds.

AI-enabled drug discovery was among the areas attracting investor attention. Anew Labs, a Shanghai-based AI drug discovery company spun out of ByteDance, raised US$290 million in a round led by HSG, IDG Capital and GL Ventures, according to the report.

Other AI-focused biotechnology companies also secured financing during September, including NUTSHELL Therapeutics, Aifei Intelligent Pharma and Pamplona Therapeutics.

These transactions illustrate the range of approaches attracting capital, from computational drug discovery and target identification to the development of new therapeutic candidates. Financing announcements alone, however, do not establish clinical effectiveness or commercial success. The value of each platform will ultimately depend on factors such as the quality of its scientific evidence, development progress and ability to translate research into viable medicines.

Out-Licensing Continues to Connect Chinese Innovation with Global Pharmaceutical Companies

September also saw substantial activity in international licensing.

PharmaDJ reported 15 out-licensing transactions involving Chinese biotechnology companies, with approximately US$1.05 billion in upfront payments and US$14.65 billion in total potential deal value.

The report identified transactions involving global pharmaceutical companies including GSK, Merck & Co., Novo Nordisk, Eli Lilly, Roche and Novartis. The licensed assets covered areas such as oncology, metabolic disease, immunology and radioligand therapy.

Several examples illustrate the range of transaction structures being used:

• Merck & Co. and SciBrunch Therapeutics: Merck licensed rights to a preclinical oral KRAS G12D inhibitor, SPR2015, in a transaction reported at US$400 million upfront and up to US$2.13 billion in total potential value.
• Novo Nordisk and Jiangsu Hengrui Pharmaceuticals: Novo Nordisk licensed Hengrui’s HRS-1596, an oral GLP-1/GIP dual agonist, in a deal reported at US$300 million upfront and up to US$2.6 billion in total potential value.
• Novartis and Abogen Biosciences: Announced on October 2, the mRNA-based therapeutics agreement provides Abogen with US$575 million upfront, with the potential for an additional US$7.2 billion in development and regulatory-related payments.

These reported terms come from published industry reporting and the Reuters report on the Abogen–Novartis transaction. The agreements differ in asset scope, development stage, rights granted and payment conditions; their headline values should not be treated as directly comparable measures of realized revenue.

What These Developments Mean for Biopharma Companies

The September activity and subsequent licensing announcements highlight several developments relevant to biotechnology companies considering fundraising or international partnerships.

1. Financing and licensing can serve different strategic purposes.

Equity financing can support research, clinical development and organizational growth while allowing a company to retain greater control over its assets. Licensing can provide upfront capital and access to a partner’s development, regulatory or commercialization capabilities, often in exchange for defined rights to an asset or technology.

The appropriate route depends on a company’s cash requirements, development stage, strategic priorities and willingness to share future economics.

2. Scientific differentiation needs to be supported by development evidence.

Investor interest in AI drug discovery and emerging therapeutic platforms does not eliminate the risks associated with drug development. Companies still need credible data, a clear development strategy, intellectual property protection and realistic plans for clinical and regulatory milestones.

3. International partnerships require more than an attractive headline valuation.

For an out-licensing transaction, upfront payments, development milestones, regulatory milestones, sales milestones, royalties and retained rights can have different economic implications. The contractual details determine how value and risk are distributed between the parties.

Companies evaluating international partnerships should also consider the partner’s development capabilities, geographic coverage, funding capacity and commitment to advancing the asset.

4. Headline deal values should be evaluated alongside execution risk.

Potential transaction values may include payments that become due only after future clinical, regulatory or commercial milestones are achieved. Upfront payments, near-term obligations and contingent payments should therefore be assessed separately when comparing transactions.

Market Context and Data Limitations

The financing and licensing figures cited here are based on PharmaDJ’s China Biopharma Tracker – September 2026, published October 13, 2026. The reported financing total and aggregate potential licensing value reflect the transactions and methodology covered by that source. Different databases may use different inclusion criteria, currency conventions and definitions of transaction value.

The transactions discussed above are examples of announced activity, not evidence that all contracted payments have been received or that the underlying drug candidates will ultimately succeed.

As companies and investors assess the market, the central questions remain the quality of the underlying science, the capital required to reach meaningful milestones, the terms of potential partnerships and the ability to execute development and commercialization plans.

Sources

1. PharmaDJ — China Biopharma Tracker: September 2026, published October 13, 2026.
2. Reuters — Novartis strikes up to $7.8 billion mRNA deal with China’s Abogen, published October 2, 2026.
3. Reuters Breakingviews — China’s biotech ingenuity extends to dealmaking, published October 16, 2026.

This article is for general industry information only and does not constitute investment, legal or medical advice.

Related Topics: Biopharma Financing · China Biotech · Licensing & Business Development · Cross-Border Transactions